Sensei Biotherapeutics (NASDAQ:FTH) Stock Gets Price Target Cut from Guggenheim

Sensei Biotherapeutics (NASDAQ:FTH) had its price objective decreased by Guggenheim from $70.00 to $69.00 in a report published on Wednesday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other research firms also recently weighed in on FTH. William Blair started coverage on Sensei Biotherapeutics in a research report on Friday, October 16th. They set an “outperform” rating for the company. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. BTIG Research reiterated a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, October 27th. TD Cowen began coverage on Sensei Biotherapeutics in a report on Wednesday, September 9th. They set a “buy” rating for the company. Finally, Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They set a “buy” rating and a $56.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.17.

Sensei Biotherapeutics Stock Performance

FTH stock traded up $2.13 during trading on Wednesday, hitting $22.05. The company had a trading volume of 535,104 shares, compared to its average volume of 376,564. The company has a 50-day simple moving average of $27.46. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $42.14. The company has a market cap of $569.77 million, a PE ratio of -0.16 and a beta of -0.15.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). Equities research analysts predict that Sensei Biotherapeutics will post -13.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently made changes to their positions in FTH. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the first quarter valued at about $22,758,000. Candriam S.C.A. acquired a new position in shares of Sensei Biotherapeutics during the 3rd quarter worth about $9,542,000. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Alyeska Investment Group L.P. acquired a new position in shares of Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Finally, Bank of America Corp DE grew its position in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the period. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.